Assessing safety and success after using bevacizumab, 5-fluorouracil or placebo in primary trabeculectomy. A Prospective Randomized placebo controlled 1-Year Follow-up Study

CONCLUSION: The 12-month IOP results showed no significant differences between the groups of patients after Bevacizumab, 5-FU or placebo to augment primary MMC enhanced trabeculectomy. However, by the analysis of bleb morphology there was a significant difference in terms of central bleb area and vascularity.PMID:34749555 | DOI:10.1080/15569527.2021.2003376

Source: Cutaneous and Ocular Toxicology - November 9, 2021 Category: Toxicology Authors: Stylianos Kandarakis Anastasios Kontaxakis Leonidas Doumazos Petros Petrou Konstantinos Droutsas Demetrios Papaconstantinou Ilias Georgalas Source Type: research